In his inaugural lecture in this series, Professor Ken Bagshawe hoped that his successors 'will not shrink from controversy or unwheeling contemporary bandwagons' (Bagshawe, 1989) . The Association of Cancer Physicians has now asked me to inspect, on their behalf, one of the biggest of all bandwagons, modem basic cancer research. You would not wish me to unwheel, even if I could, a vehicle with so many passengers, but you are concerned about its direction and its rate of progress, an impatience ironically acknowledged in Professor Bagshawe's original title for his lecture; 'Whilst waiting for the human genome to be mapped'. Like all mechanics, I am underneath this bandwagon looking up and, despite erratic steering and a lumbering forward motion, it seems quite capable of reaching its destination if carefully handled. I hope to persuade you of this by examining, firstly, our current understanding of cancer biology, secondly, the prospects this offers for better management and, finally, ways to encourage the translation of understanding into practice.
The biologist's view of cancer
Like most long-standing endeavours, the present status of basic cancer research is only fully explicable by reference to its history. The original impetus to know more about cancer came from the problems of managing the cancer patient and laboratory investigations were intended, directly or indirectly, to aid this management. The knowledge gained from this 'top down' approach and, in particular, the finding that a single cancer cell could form a tumour in a recipient animal, led to the cancer cell supplanting the cancer patient as the unit of interest to many biologists. There developed the large body of 'bottom up' cancer research, that tackled problems generated at the cellular level and whose reductionist view was greatly abetted by the development of in vitro cell culture systems, particularly those exploiting tumour viruses and the power of classical molecular genetics ( Figure 1 ).
This latter approach has proved enormously fruitful, leading in turn to the identification of viral genes that induce neoplasia, to the discovery of normal cell homologues (protooncogenes) for some of these viral oncogenes and to the implication of proto-oncogene mutations in many naturallyoccurring cancers. These findings, in total, impressively validate the concept that somatic mutations in the neoplastic cell lineage underlie the altered growth and behaviour that typify cancer. Moreover, functions were assigned to many proto-oncogene products that seemingly explained their ability to perturb normal cell growth and behaviour. It has become axiomatic that genes whose alterations contribute to neoplasia encode products that play a role in the complex processes by which a cell perceives and responds to its environment. 'Oncoproteins' have variously been identified as molecules transmitting signals between cells, as the receptors for these ligands (either on the cell surface or inside the cell), as components of second messenger pathways or as nuclear proteins that mediate the response of the cell genome ( Figure 2). We might also expect oncoproteins to contribute to events that follow from changes in genomic activity, but clear cut examples of changes in these 'effector' pathways are so far lacking, in contrast to the probable situation with tumour suppressor genes (see below, Fearon et al., 1990; Pignatelli & Bodmer, 1988) . The signalling pathways in which oncoproteins have been implicated have generally been those favouring cell multiplication at the expense of terminal differentiation ( Figure 2 ) but it must be emphasised that in no case (with the possible exception of oncoproteins cognate with intracellular hormone receptors) do we understand in detail the circuits disrupted by oncogenic mutations.
The success of the reductionist approach warrants its continuation for as long as we can ask significant questions about the cancer cell and the issue of matching this research to the management of the patient is rightly irrelevant to its justification. However, over the past decade the molecular biologist has come to appreciate the complexity of neoplasia that has long been apparent to the pathologist and physician and the limitations of pure reductionism have been exposed. The viral oncogene paradigm and its conceptual descendants provide an inherent bias to the detection of genetic alterations that, on their own, confer on a normal cell phenotypically dominant altered growth. Attention has thus been diverted from, and is only recently returning to, the following crucial facets of neoplasia.
Clinical
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Can~~~~~~~cer cell ? Figure 1 The structure of cancer research, depicted as a pyramid whose apex is the desired solution to managing all or part of the problem. Questions initially posed by attempts at patient management stimulated both clinical research (top of pyramid) and 'top down' laboratory work (filled arrowheads). The latter soon led to broadly-based, self-justifying 'bottom up' investigations, based on the cancer cell (cross-hatched arrowheads). The two types of laboratory work were, until recently, generally distinguishable in concepts and techniques, but they are now merging as the principles of basic research are applied to problems posed by the patient and should soon impinge on clinical practice. (Weinberg, 1989) . Information on this point from the well-tried experimental systems retained, however, the bias to identifying what were then considered to be dominantly acting oncogenes.
Tumour suppression The concept that recessive (loss of function) mutations contribute as much, or more, to neoplasia than dominant (change of level or function) mutations is now a major bandwagon in its own right (Klein, 1987 (Fearon et al., 1990 There is growing evidence that tumour suppressor gene and oncogene functions occupy comparable niches in cellular physiology, with the former mediating processes that favour differentiation over cell multiplication (Figure 2 (Paraskeva & Williams, 1990; Sobel, 1990; Weinberg, 1989 (Cairns, 1989) (Wyke, 1990) . Viruses implicated in human cancer are generally widespread agents and neoplasia is characteristically associated with chronic infection, acquired early in life and accompanied by immune impairment and exposure to co-carcinogens. A significant risk of neoplasia may thus only exist for a subset of the population and there may be a lag of a generation before benefits accrue from immunisation. These factors mean that the benefits of vaccination must be weighed carefully against its costs and risks unless, as with hepatitis B, the virus poses a major nonneoplastic risk to health.
Consideration of viral carcinogenesis leads us to another aspect of cancer avoidance that may benefit from deeper biological understanding. Controlled breeding and intensive husbandry in the domestic fowl have shown that susceptibility to the commonest form of cancer is widespread and inherited in a dominant fashion. The reason has been known for 30 years. In domestication, the retroviruses of the avian sarcoma/leukosis complex are the predominant carcinogens and they can only infect birds that express cellular receptors for the viral envelope glycoproteins. Such clear-cut predisposition to neoplasia is only rarely seen in human populations that are generally outbred and exposed to varying environmental influences, but the possibility of more subtle and ubiquitous variations in inherited proneness to cancer is now receiving attention (for example, Law, 1990 ). If we understand the undoubtedly complex factors that determine such variations then we can tackle the even more difficult problem of deciding how to use such knowledge.
In the even longer term, there are two other prospects for cancer avoidance, and the fowl again provides an example of the first. If a strain of chickens is susceptible to virus-induced neoplasia because it expresses the cellular receptor for a common retrovirus type, then it is possible to abrogate this susceptibility by manipulation of the chicken genome. Classical breeding has achieved this in some instances but transgenesis now provides, in theory, two other options. Site specific recombination can be used to ablate the gene encoding the viral receptor or the receptor can be blocked by introducing into the bird a vector expressing the viral envelope glycoprotein. We do not know, however, the physiological role of the receptor molecule, so we are unable to predict the consequences of either its loss or permanent association with the viral glycoprotein ligand. Such uncertainties may only be resolved by studying the transgenic animal and thus practical, as well as ethical, considerations may largely limit this type of intervention to veterinary subjects.
The other long term prospect is the improved detection of environmental carcinogens. At present a battery of tests are used to predict carcinogenicity or mutagenicity but these do not examine the precise pathways by which carcinogens exert their effects. However, once the details of carcinogenesis are understood it may be possible to devise tests that predict more exactly the consequences of exposure to a given agent. This knowledge will help in deciding appropriate safety controls as well as in monitoring the effects of untoward exposure. In a broader context, and one that is even more difficult to predict, a greater understanding of mechanisms may help in elucidating the causes of those common cancers in which environmental influences are suspected but not defined. This should be a very important goal, but epidemiological successes do not necessarily lead to improved cancer management if their implications run counter to social and political trends. Political considerations also apply to the next aspect of management that will benefit from basic knowledge.
Screening and early detection of cancer I am not qualified to comment on the economic, social and psychological ramifications of detecting cancer at an earlier stage but, objectively, early detection may increase, and should never reduce, the patient's lifespan. However, although biologists may leave others to decide the desirability of screening in specific instances, they have to recognise that any potential screening strategies spawned by basic research should be simple, cheap, precise, easy to interpret and acceptable to the population to be screened.
These are severe and sometimes opposing constraints to place on the detection of a complex and subtle disease in which a series of genetic alterations lead to either qualitative or quantitative changes in gene products. Thus, simplicity, economy and, to a lesser extent, precision, are best satisfied by screening for gene products that invariably undergo tumour-specific qualitative changes that can be detected with high sensitivity, probably by immunological means. Acceptability would be enormously enhanced if these changes could be perceived in samples obtained by non-invasive means, presumably biasing this approach to tumours of the exocrine organs and the respiratory, alimentary and urogenital tracts where, fortunately, many important human cancers occur. It will not be easy to discover tumour cell products with these stringent characteristics.
In contrast, the most precise and easily interpreted changes are those to the DNA of tumour cells, but it has been difficult to see how genetic alterations to a small number of cells could be detected with high sensitivity and patient compliance. The rapid exploitation of the polymerase chain reaction (PCR) in the past few years looks set to solve the problem of sensitivity if not acceptability (McCormick, 1989) . However, just as detailed knowledge of protein alterations are essential to devising immunological probes, so we must understand preci-sely the sites of mutations in tumours to design oligonucleotide primers for PCR. The inescapable conclusion is that more basic information is needed to underpin new screening strategies.
Diagnosis and prognosis Even without the development of new early detection methods, existing screens for carcinoma of the cervix and breast will produce false positives that need rapid resolution, adding to an important demand on expert diagnostic services. There is thus a clear incentive to ask whether our new knowledge of cancer will allow diagnosis to become easier and cheaper without sacrificing its accuracy. It is also important to know whether prognosis can be made more precise, particularly in predicting response to therapy and thus contributing more to the management of the disease. In addition there is a need for more effective monitoring of the establishment and maintenance of remission in patients already receiving treatment.
The approaches which basic research can bring to bear on these needs are similar to those which can be applied to early detection, notably antibody probes for tumour-specific proteins and nucleic acid probes for genetic alterations. However, applications in diagnosis and prognosis are greater and constraints are less. Indeed, although monitoring remission for incipient relapse shares many of the problems of early detection, it is relatively free of the need for simplicity, low cost and patient compliance and can, moreover, be tailored to individual patients. Thus, overall, this is the first facet of cancer management in which our new biological understanding is likely to have an impact. Monoclonal antibodies for immune histochemistry are readily used and may soon be supplemented by 'single domain antibodies', themselves a result of exploiting PCR technology (Ward et al., 1989 At present, indeed, the limitations to applying molecular biology to diagnosis are not in the techniques but in our ability to interpret the results, and until our understanding is more profound that will restrict implications for cancer management. One example illustrates these points. The Philadelphia chromosomes are produced by translocations that fuse the 5' end of the phl (BCR) gene on chromosome 22 to a decapitated c-abl gene from chromosome 9, the hybrid gene producing mRNA transcripts and protein products that are unique to chronic myeloid leukaemia (CML). Although the breakpoints on chromosome 22 in CML occur in a limited region (Figure 4a ), they do show variations that modify the structure of the phl-abl hybrid gene and several groups have tried to correlate these variations with the clinical course of CML. Birnie et al. (1989) have discussed these studies and proposed, as a consensus, that breakpoints with a more 5' location in phl are found more frequently in patients with a longer chronic phase to the disease (Figure 4b ), although this conclusion remains in dispute (Jaubert et al., 1990) . Clearly, more basic information is needed to decide whether and how chromosome 22 breakpoint positions influence CML prognosis and only then can it be determined whether this information will influence patient management.
Aids to existing cytotoxic therapies Cancer physicians are most excited by the scope basic understanding of cancer offers for new and improved treatments. Prospects for therapy are of two types; adjuncts to existing treatments or radically new approaches to treatment, the former probably entering clinical research and practice before the latter.
Some ways of improving existing cytotoxic chemotherapy or radiotherapy are listed in Table I (Graham et al., 1990 ). This molecule, by inhibiting bone marrow stem cell growth, may protect them from cytotoxic drugs, although it should be remembered that many drug regimes affect the haemopoietic progenitor cell compartment rather than stem cells. It is possible that the inhibitor may also affect stem cells of other lineages, broadening the scope for its therapeutic use. 4. A strategy that is currently receiving much attention is the use of growth stimulatory molecules to encourage the regeneration of tissues damaged by cytotoxic agents. The use of haemopoietic colony stimulating factors to achieve rapid and effective recovery of the progenitor cell compartment is a good example of this approach (Crowther et al., 1990 Table II , from which it can be seen that the strategies are heavily dependent on the knowledge acquired from reductionist studies. Moreover, since these gambits are aimed at the very changes that render a cell neoplastic there seem few ways for the tumour to become refractory to treatment without, at the same time, ceasing to grow or behave abnormally. Nonetheless, we should remember that the concept of reimposing homeostasis in its broader sense is not novel, having been applied in the use of antiendocrines to treat hormone responsive tumours.
We shall consider in turn the options listed in Table II . 1. A popular view of neoplasia represents it as resulting from a failure to complete a normal cell differentiation programme. If true, the corollary of this concept is that neoplasia would be cured by inducing the tumour cells to differentiate. The processes that determine normal differentiation are not fully understood for any lineage but roles have been postulated for small molecules, such as retinoic acid, dihydroxy vitamin D3 and cyclic AMP, as well as for protein factors. The effects of many such agents have been tested on various tumour cells and some were, indeed, first identified as activities that inhibited tumour cell growth, but their therapeutic exploitation is not straightforward.
First, as alluded to earlier, the activity of factors implicated in differentiation can be very dependent on their (Gough & Williams, 1989) .
A second concern is that some neoplasias may arise in part because they no longer respond to normal induction of differentiation, so they will be refractory to the therapeutic use of inducers. TGF-P, first described as a transformed cell growth factor, is a growth inhibitor in most contexts but some tumours do not respond to it because of changes at a receptor or post-receptor level. Indeed, the tumour-promoting effect of the phorbol ester TPA in experimental skin carcinogenesis may be explained paradoxically by its ability to increase TGF-P production, which inhibits the growth of normal keratinocytes and thus favours the outgrowth of unresponsive neoplastically initiated cells (Parkinson & Balmain, 1990) . In a wider context, inducers of differentiation can be regarded as extracellular components of the tumour suppressor pathway depicted in Figure 2 . As such, they are only likely to be deficient in cancer patients if their production is normally limited to a particular stage of development or if their tissues of origin are defective. With greater knowledge we can examine these possibilties and determine whether there are abnormalities which lead to a correctable cancer susceptibility. 2. The concept of using antisense oligonucleotides to inhibit tumour specific gene expression is appealing but its problems have recently been reviewed (Rothenberg et al., 1989 In practice, a number of oncoproteins function aberrantly because they no longer respond to the cellular molecules that regulate their activity, making this an unpromising point of attack. Biosynthesis seems, however, more vulnerable and, for example, Ras oncoprotein function could be inhibited by preventing the covalent attachment of farnesyl residues to the protein, a metabolic step essential for anchoring the protein in the plasma membrane. Goldstein and Brown (1990) suggested that the putative Ras farnesyl-protein transferase would be a highly specific target for such inhibition whilst, less specifically, Schafer et al. (1989) (Akiyama et al., 1987) .
Specific tyrosine kinase inhibition can, on the other hand, be displayed by the tyrophostins, a class of synthetic, soluble, low molecular weight compounds that compete, not with ATP, but with the tyrosine-containing substrate of the enzymes. Some of these molecules, patterned on the actinomycete product, erbstatin, inhibit the epidermal growth factor receptor tyrosine kinase I02-i0I fold more efficiently than they block the closely related insulin receptor kinase (Gazit et al., 1989) . Moreover, the consequences of this inhibition can be demonstrated in vivo, where the effects are reversible (Yaish et al., 1988) . Thus, despite the similarity in the catalytic domains of tyrosine kinases, it seems it will be possible to develop specific inhibitors for individual enzymes. 4. These results are encouraging but they do not avoid the concern that, by inhibiting an activated oncoprotein, an essential normal homologue might also be impaired in tissues other than the tumour. If, however, the loss of a tumour suppressor gene function is known to be important in the genesis of a given tumour, then the replacement of that activity would probably be less hazardous for normal cells. Our knowledge of tumour suppressor genes is at present too rudimentary to give promising instances of this approach. Introduction of the Rb tumour suppressor gene into retinoblastoma cells can suppress their tumorigenicity (Huang et al., 1988) but it is, at present, difficult to see how such gene replacement can be applied to cancer patients. The replacement of the missing tumour suppressor protein may be a more feasible option but perhaps the greatest hope lies with the design of molecules that substitute for the missing function and are small and stable enough to enter and act in the cells of the tumour. A great deal more must be learned about tumour suppressor genes before we can realistically anticipate the development of such compounds.
Putting theory into practice A recurring theme in my argument has been the need for more basic knowledge to underpin promising practical applications. Clearly, clinicians must wait some time yet to see how our new understanding of cancer will influence their work, but it is not too early to consider how best to translate anticipated laboratory advances into clinical practice. A crucial element in this development will be the availability of workers with a true understanding of the concepts and techniques of modern molecular and cell biology linked to an equally full appreciation of the requirements for effective cancer management. Such personnel are essential if the confluence of laboratory and clinical research is to avoid the misunderstanding and disappointed expectations which dampen enthusiasm and encourage conservative attitudes in both camps.
For some time, the usual way to equip workers for the difficult role of bridging laboratory and clinical studies has been to train medical graduates in laboratory science, on the assumption that they will apply their appreciation of basic research throughout their subsequent clinical careers. This stratagem has lately been questioned on the grounds that clinical demands are too great to be combined with excellence in research and teaching (Arias, 1989) . It was proposed, instead, that the bridge could be formed by laboratory researchers who received additional training in clinical sciences. Such a development is desirable, but as an adjunct and not an alternative to the informed clinician. The laboratory worker who understands the problems of patient management will be invaluable in effecting the close interdigitation of 'top up' and 'bottom down' research ( Figure 1 ) but will still have to rely on the clinician to apply new knowledge to the patient. Successful practical applications will become increasingly improbable if other pressures force clinicians to lose touch with advances in basic research.
Paradoxically, as our knowledge of cancer becomes more sophisticated it is more, not less, vital for the cancer physician not to abandon the field to the basic biologist. It is thus essential that motivated clinicians take time from their commitments to patients to keep fully abreast of new concepts and technology.
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